Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FE 999049 (Rekovelle) for Idiopathic Male Infertility
2023-508430-34-00Phase 2Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Nov 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in unexplained male infertility (UMI) and oligoasthenospermia (OA) comparing Rekovelle (follitropin delta) with Placebo (2 arms). Primary endpoint: Spontaneous pregnancy in female partner within 9 months. Started Nov 2023; status: completed.
02
Drugs
recombinant human follicle stimulating hormone
03
Conditions
unexplained male infertility (UMI)oligoasthenospermia (OA)
Beyond the preview
Go deeper on 2023-508430-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508430-34-00.